Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9152280 | 1.00 | RECQL (0.34) | RECQLTDP1KDM4EMEN1USP2 | |
| SCHEMBL487224 | 0.91 | — | — | |
| Alcohol SCHEMBL28389285 | 0.88 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL17743846 | 0.80 | RECQL (0.46) | RECQLTDP1KDM4EMEN1USP2 | |
| SCHEMBL11074534 | 0.79 | PTPN7 (0.50) | RECQLTDP1KDM4EMEN1USP2 | |
| SCHEMBL8580513 | 0.78 | — | — | |
| SCHEMBL8775393 | 0.77 | PTPN7 (0.59) | RECQLTDP1KDM4EMEN1USP2 | |
| SCHEMBL3407843 | 0.77 | — | — | |
| SCHEMBL233042 | 0.77 | RECQL (0.37) | RECQLTDP1KDM4EMEN1USP2 | |
| SCHEMBL10809685 | 0.77 | KDM4E (0.31) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115466162-A | Process for preparing (cis ) -3,6, 9-nonadecatriene | 虫捕头(苏州)生物科技有限公司 | 2022-12-13 | — | — | CN | claimed |
| CN-115466162-A | Process for preparing (cis ) -3,6, 9-nonadecatriene | 虫捕头(苏州)生物科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-9663444-B2 | Heteroatom containing substituted fatty acids | COMPLEXA, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170113999-A9 | HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS | COMPLEXA, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20140336397-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED DHA AND USE AS A REFERENCE STANDARD | MED-LIFE DISCOVERIES LP (CA) | 2014-11-13 | — | — | US | disclosed |
| US-20140256814-A1 | HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS | COMPLEXA, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| EP-2483233-A2 | HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS | Miller, Raymond A. (US) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011041639-A2 | HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS | MILLER RAYMOND A (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20110082206-A1 | HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS | COMPLEXA, INC. | 2011-04-07 | — | — | US | disclosed |
| US-20050222253-A1 | Anti-cancer nitro- and thia-fatty acids | FERRANTE ANTONIO | 2005-10-06 | — | — | US | disclosed |
| US-6924309-B2 | Anti-inflammatory nitro and thia-fatty acids | CHILDREN, YOUTH AND WOMEN'S HEALTH SERVICE INCORPORATED (AU) | 2005-08-02 | — | — | US | disclosed |
| US-20040254240-A1 | Anti-cancer nitro- and thia-fatty acids | FERRANTE ANTONIO (AU) | 2004-12-16 | — | — | US | disclosed |
| EP-1218333-A4 | ANTI-INFLAMMATORY NITRO- AND THIA- FATTY ACIDS | WOMENS & CHILDRENS HOSPITAL (AU) | 2003-07-09 | — | — | EP | disclosed |
| EP-1218000-A4 | ANTI-CANCER NITRO- AND THIA-FATTY ACIDS | WOMENS & CHILDRENS HOSPITAL (AU) | 2003-07-09 | — | — | EP | disclosed |
| US-20030092762-A1 | Anti-inflammatory nitro and thia-fatty acids | PEPLIN BIOLIPIDS PTY LTD (AU) | 2003-05-15 | — | — | US | disclosed |
| US-20030078299-A1 | Anti-cancer nitro- and thia-fatty acids | CHILDREN, YOUTH AND WOMEN'S HEALTH SERVICE INCORPORATED (AU) | 2003-04-24 | — | — | US | disclosed |
| EP-1218000-A1 | ANTI-CANCER NITRO- AND THIA-FATTY ACIDS | WOMEN'S AND CHILDREN'S HOSPITAL (AU) | 2002-07-03 | — | — | EP | disclosed |
| EP-1218333-A1 | ANTI-INFLAMMATORY NITRO- AND THIA- FATTY ACIDS | WOMEN'S AND CHILDREN'S HOSPITAL (AU) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021172-A1 | ANTI-CANCER NITRO- AND THIA-FATTY ACIDS | WOMEN'S AND CHILDREN'S HOSPITAL ADELAIDE (AU) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001021575-A1 | ANTI-INFLAMMATORY NITRO- AND THIA- FATTY ACIDS | WOMEN'S AND CHILDREN'S HOSPITAL ADELAIDE (AU) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254240-A1 | Anti-cancer nitro- and thia-fatty acids | ALOX5, ALOX15, ALOX12 | RECQL 2892/4885TDP1 2094/4885KDM4E 2754/4885 |
| US-20030078299-A1 | Anti-cancer nitro- and thia-fatty acids | ALOX5, ALOX15, ALOX12 | RECQL 3103/4885TDP1 2376/4885KDM4E 2651/4885 |
| US-20050222253-A1 | Anti-cancer nitro- and thia-fatty acids | ALOX5, ALOX15, ALOX12 | RECQL 2759/4885TDP1 2099/4885KDM4E 2689/4885 |
| US-20170113999-A9 | HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS | FFAR2, FFAR1, FFAR4 | RECQL 4500/4885TDP1 4591/4885KDM4E 4668/4885 |
| US-20140256814-A1 | HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS | FFAR2, FFAR1, FFAR4 | RECQL 4500/4885TDP1 4591/4885KDM4E 4668/4885 |
| US-20140336397-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED DHA AND USE AS A REFERENCE STANDARD | FASN, ALOX5, ALOX15 | RECQL 4324/4885TDP1 2746/4885KDM4E 2160/4885 |
| US-20030092762-A1 | Anti-inflammatory nitro and thia-fatty acids | PTGES2, PTGES, PTGS2 | RECQL 3400/4885TDP1 3098/4885KDM4E 3214/4885 |
| US-20110082206-A1 | HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS | FFAR2, FFAR1, FFAR4 | RECQL 4500/4885TDP1 4591/4885KDM4E 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.